Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Description

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

Conditions

Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy

Study Overview

Study Details

Study overview

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

Sacral Neuromodulation for Male Overactive Bladder

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Condition
Overactive Bladder
Intervention / Treatment

-

Contacts and Locations

Shreveport

WK Clinical Research, Shreveport, Louisiana, United States, 71103

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Participants aged ≥ 18 years at the time of enrollment
  • 2. Able to complete bladder diaries and patient questionnaires
  • 3. Primary diagnosis of Urinary Urgency Incontinence (UUI)
  • 4. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year
  • 5. Underwent prostatectomy for prostate cancer at least 6 months prior to enrollment
  • 6. Underwent radiation therapy for prostate cancer at least 6 months prior to enrollment
  • 7. Underwent cytoreductive surgical intervention for BPH at least 6 months prior to enrollment
  • 1. Any patient that is not a suitable candidate per investigator discretion
  • 2. Recent prostate therapy or procedure within the last 6 months at the time of enrollment
  • 3. Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)
  • 4. Previously implanted with a sacral neuromodulation device, including inactive SNM devices
  • 5. Any prior treatment with an Implantable Tibial Nerve Stimulation (ITNS)
  • 6. Percutaneous Tibial Nerve Stimulation (PTNS) within the last 3 months at the time of enrollment
  • 7. Underwent an external trial with any sacral neuromodulation device and was deemed a non-responder by a physician
  • 8. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study objectives (e.g. Crohn's disease, moderate to severe fibromyalgia, chronic pain)
  • 9. Uncontrolled diabetes
  • 10. Known allergic reactions to components of the Axonics SNM System, including titanium, zirconia, polyurethane, epoxy, or silicone

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Axonics, Inc.,

Karen Noblett, MD, STUDY_DIRECTOR, Axonics, Inc.

Study Record Dates

2027-03